Arovella Therapeutics Limited (AU:ALA) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arovella Therapeutics Ltd, an Australian biotechnology firm, is set to conduct an investor webinar discussing advancements in its iNKT cell therapy platform, following a successful pre-IND meeting with the FDA and progress in their CAR-iNKT manufacturing process. The webinar, led by CEO Dr. Michael Baker, will outline next steps for the company’s lead product, ALA-101, targeting CD19-positive blood cancers. Interested parties can register for the event scheduled for September 18, 2024, with the recording to be accessible post-event on the company’s website and social media.
For further insights into AU:ALA stock, check out TipRanks’ Stock Analysis page.